Search Results

BioPharmX Corporation (NYSE American: BPMX) (“BioPharmX”) today announced that all proposals related to its proposed merger with Timber Pharmaceuticals LLC (“Timber”) were approved by BioPharmX’s stockholders at a special meeting held on May 13, 2020.

BioPharmX Corporation (NYSE American: BPMX) (“BioPharmX”) is urging its stockholders to vote now on the proposed merger of BioPharmX with Timber Pharmaceuticals LLC (“Timber”) and related matters as described in the proxy statement/prospectus.

BioPharmX Corporation announced that the date of its special stockholders’ meeting to consider and vote on the proposed merger of BioPharmX with Timber Pharmaceuticals LLC and related matters has been changed.

BioPharmX Corporation and Timber Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and commercialization of treatments for orphan dermatologic diseases, announced that they have entered into a definitive merger agreement.

BioPharmX Corporation (NYSE American: BPMX) (“BioPharmX” or the “Company”), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today announced that, in anticipation of closing its merger with Timber Pharmaceuticals, it will effect a 1-for-12 reverse stock split of its outstanding common stock.

BioPharmX Corporation received notification on March 24, 2020 from the NYSE American LLC that the NYSE American has determined it will commence proceedings to delist the Company’s stock from its Exchange

BioPharmX Corporation announced that its Board of Directors has approved a reverse stock split of its common stock at a ratio of 1-for-25.

BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today reports financial results for the fiscal quarter ended October 31, 2019.

BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today reports financial results for the quarter ended April 30, 2019.

BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today reports financial results for the fiscal quarter ended July 31, 2019.